The TSRI team is now actively seeking a pharmaceutical company partner or other funding to sponsor clinical trials.
“This deal is the latest example of our corporate partnership strategy,” says Scott Forrest, TSRI’s vice president for business development.
The findings from the MacRae lab open the door to a new class of therapies.
Work from the Wu lab shows a little-understood mechanism, although error-prone, has an overall protective role.